1 December 2021
Oncode spin-off Immagene announces seed investment round to progress novel Immuno-Oncology therapeutics
Immagene B.V., a spin-off of the Netherlands Cancer Institute (NKI) and Oncode Institute, today announces it has raised a seed financing round to advance its next-generation precision Immuno-Oncology (IO) therapeutics. BOM Brabant Ventures joined as a new investor with additional support from existing investors Swanbridge Capital and Oncode Oncology Bridge Fund.
30 November 2021
More than science: highlights from the Oncode CGC Annual Conference
Did you attend Oncode’s Annual Conference at the Royal Tropical Institute at the beginning of November? If not, you’ve been missing out. Was it the wide variety of topics presented by a great mix of experts who delivered their knowledge with passion and insight, both in person and online? Was it the energy and joy that came from being able to get together face to face, right before a new lockdown? In any case, make sure to check out the highlights!
29 November 2021
CPoC grants awarded: New treatments for vulvar cancer & malignant mesothelioma
Oncode Institute aims to link fundamental and clinical research to enable efficient translation of promising findings into novel diagnostic methods and clinical treatment strategies. Oncode created the clinical Proof-of-Concept (cPoC) fund to support the clinical translation of Oncode’s fundamental research. Oncode Institute is pleased to announce that the 14th and 15th grants within the Clinical Proof of Concept programme have been awarded: less radical treatments for vulvar cancer and new drug combinations for malignant mesothelioma.
25 November 2021
Oncode shows it can be done in a different way: an interview with Hans Clevers
How can we as a society benefit even more from the knowledge that is being developed at our Dutch universities? How do you transfer this knowledge into innovations that boost our economy and offer solutions to our major societal challenges? These are some of the questions at the core of Oncode Institute. Oncode Investigator Hans Clevers, co-founder of Oncode Institute and professor Molecular Genetics at Utrecht University and UMC Utrecht answers them in this interview conducted by Teachleap.nl in collaboration with Innovation Origins.
25 November 2021
Oncode Investigator Sylvie Noordermeer: ‘Setting up your own research group is both exciting ánd terrifying’
Creating your own research group is exciting, but what are some of the typical challenges that can emerge? Oncode Investigator Sylvie Noordermeer (LUMC) discusses her experiences as founder of the Noordermeer research group, whilst also reflecting on the contribution that Oncode’s Mentoring Programme can make in solving dilemmas.
Fundamental science, clinical testing and a sharp mind for market opportunities: at Oncode we bring it all together to create impact for patients.
Scroll for more